SDIX To Report Third Quarter 2012 Results On November 12, 2012
SDIX (Nasdaq: SDIX) - a leading provider of biotechnology-based
products and services for a broad range of life science, biotechnology
and diagnostic applications - expects to release its third quarter 2012
SDIX (Nasdaq: SDIX) - a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology and diagnostic applications - expects to release its third quarter 2012 results at approximately 4 p.m. ET on Monday, November 12, 2012. The Company has scheduled an investor conference call for 4:30 p.m. ET on the same day. The dial-in number for the live conference call will be 877-407-8035 (201-689-8035 outside the U.S.). A live webcast of the conference call will be available on the Company’s website, www.sdix.com, as well as www.investorcalendar.com. For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on November 12, 2012 through 11:59 p.m. ET on November 26, 2012. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 403556. About SDIX ( www.sdix.com) SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical and biotechnology markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives. SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.
Shares of Strategic Diagnostics (Nasdaq:SDIX) have taken a tremendous swing upward. The stock is trading at $2.68 as of 12:22 p.m. ET, 20.7% above Thursday's closing price of $2.22. Volume is at 295,904, 8.7 times the daily average of 34,200.